SCHEMBL2367599

SCHEMBL2367599

Cc1ccc(C)c2c1[nH]c1c(NS(=O)(=O)c3ccccc3)cccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.51
ALDH1A1 P00352 4/20 0.51
LMNA P02545 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PKM P14618 1/20 0.51
SLC40A1 Q9NP59 6/20 0.48
IMPDH2 P12268 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
BRD4 O60885 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
AGTR1 P30556 1/20 0.44
GLO1 Q04760 1/20 0.44
PAX8 Q06710 1/20 0.44
HTT P42858 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367251 0.91 KEAP1 (0.54) ALDH1A1LMNAKDM4EPKMSLC40A1
SCHEMBL2367619 0.89 ALDH1A1 (0.56) ALDH1A1LMNAKDM4ESLC40A1BRD4
SCHEMBL2367468 0.89 HTR6 (0.49) ALDH1A1LMNAKDM4EPKMKMT2A
SCHEMBL2367596 0.89 CA1 (0.56) ALDH1A1LMNAKDM4EPKMKEAP1
SCHEMBL2367618 0.87 KEAP1 (0.57) ALDH1A1LMNAPKMSLC40A1KMT2A
SCHEMBL2368052 0.86 MAPT (0.48) ALDH1A1LMNAKMT2AMEN1MAPT
SCHEMBL2367200 0.84 CLK1 (0.53) LMNASLC40A1KMT2AMEN1GAA
SCHEMBL2367721 0.81 KEAP1 (0.44) ALDH1A1LMNAPKMSLC40A1KMT2A
SCHEMBL5948574 0.81 KEAP1 (0.43) ALDH1A1LMNASLC40A1KMT2AMEN1
SCHEMBL2367609 0.80 GAA (0.53) ALDH1A1PKMSLC40A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 EP disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
CN-102199148-A Benzenesulfonamide derivatives and pharmaceutical compositions thereof PURZER PHARMACEUTICAL CO LTD 2011-09-28 CN disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
EP-2366687-A2 Benzenesulfonamide derivatives and pharmaceutical composition thereof Purzer Pharmaceutical Co., Ltd. (CN) 2011-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof CCNI, CCNE1, CCND1 RECQL 528/4885ALDH1A1 1191/4885LMNA 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.